Physician profile
Hannah E Patrick
NPI 1528686326
$1,665.26
in general payments reported to CMS, 2019-2025
26 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $535 · 2022: $219 · 2023: $397 · 2024: $403 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Entertainment: $15.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.93 |
| Entertainment | $15.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.84 | 2021-2025 | |
| Lilly USA, LLC | $291.11 | 2021-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $163.22 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $110.43 | 2021 | |
| Glaxosmithkline, LLC. | $76.86 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $62.06 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $59.42 | 2022-2024 | Austedo Xr |
| Braeburn INC. | $56.85 | 2025 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.20 | 2021-2025 | Relistor |
| Novo Nordisk INC | $53.43 | 2021 | |
| Axsome Therapeutics, INC. | $51.33 | 2024 | Auvelity |
| Insulet Corporation | $45.53 | 2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.02 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $28.83 | 2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Corium, LLC | $24.31 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $23.76 | 2023 | Aristada, Lybalvi |
| Corcept Therapeutics | $22.58 | 2024 | Korlym |
| Hologic Sales and Service, LLC | $17.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.43 | 2024 | Rexulti |
| Sage Therapeutics, LLC | $16.21 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $15.96 | 2021 | |
| Optos, INC. | $15.64 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Indivior INC. | $13.54 | 2025 | Sublocade |
| Medtronic, INC. | $13.42 | 2021 | |
| Pfizer INC. | $13.15 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.